Quantitative analysis of O6-methylguanine DNA methyltransferase (MGMT) promoter methylation in patients with low-grade gliomas

Journal of Neuro-Oncology

Volumn 103, Issue 2, 2011, Pages 343-351

  Ochsenbein, Adrian F ^a   Schubert, Adrian D ^a   Vassella, Erik ^b   Mariani, Luigi ^c  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Chemotherapy; LOH; Low grade glioma; MGMT promoter; Temozolomide

Indexed keywords

METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; TEMOZOLOMIDE; ANTINEOPLASTIC AGENT; DACARBAZINE; DNA METHYLTRANSFERASE; DRUG DERIVATIVE; MGMT PROTEIN, HUMAN; POLYDEOXYRIBONUCLEOTIDE SYNTHASE; TUMOR SUPPRESSOR PROTEIN;

ADULT; AGED; ALLELE; ANEMIA; APHASIA; ARTICLE; ASTROCYTOMA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CANCER GRADING; CHROMOSOME 19Q; CHROMOSOME 1P; CHROMOSOME ANALYSIS; CLINICAL ARTICLE; COGNITIVE DEFECT; CONSTIPATION; CONTROLLED STUDY; DESQUAMATION; DISEASE EXACERBATION; DNA METHYLATION; DRUG RESPONSE; FEMALE; GASTROINTESTINAL DISEASE; GENOTYPE; GLIOMA; HETEROZYGOSITY LOSS; HISTOLOGY; HUMAN; HUMAN TISSUE; HYPERNATREMIA; HYPONATREMIA; LEUKOPENIA; MALE; MICROSATELLITE MARKER; MUCOSA INFLAMMATION; NAUSEA AND VOMITING; NUCLEAR MAGNETIC RESONANCE IMAGING; OLIGODENDROGLIOMA; PARALYSIS; POLYMERASE CHAIN REACTION; PROGRESSION FREE SURVIVAL; PROMOTER REGION; QUANTITATIVE ANALYSIS; RASH; RETROSPECTIVE STUDY; SEIZURE; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT DURATION; TUMOR GROWTH; TUMOR VOLUME; VERTIGO; BRAIN TUMOR; DISEASE FREE SURVIVAL; DRUG RESISTANCE; GENETICS; KAPLAN MEIER METHOD; MIDDLE AGED; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; DACARBAZINE; DISEASE-FREE SURVIVAL; DNA METHYLATION; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; DRUG RESISTANCE, NEOPLASM; FEMALE; GLIOMA; HUMANS; KAPLAN-MEIER ESTIMATE; LOSS OF HETEROZYGOSITY; MALE; MIDDLE AGED; PROMOTER REGIONS, GENETIC; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR PROTEINS;

EID: 79959830905     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-010-0395-2     Document Type: Article

References (30)

1. van den Bent MJ, Afra D, de Witte O, Ben Hassel M, Schraub S, Hoang-Xuan K, Malmstrom PO, Collette L, Pierart M, Mirimanoff R, Karim AB (2005) Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet 366:985-990 (Pubitemid 41323034)
2. Karim AB, Maat B, Hatlevoll R, Menten J, Rutten EH, Thomas DG, Mascarenhas F, Horiot JC, Parvinen LM, van Reijn M, Jager JJ, Fabrini MG, van Alphen AM, Hamers HP, Gaspar L, Noordman E, Pierart M, van Glabbeke M (1996) A randomized trial on dose-response in radiation therapy of low-grade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) Study 22844. Int J Radiat Oncol Biol Phys 36:549-556 (Pubitemid 26404297)
3. Shaw E, Arusell R, Scheithauer B, O'Fallon J, O'Neill B, Dinapoli R, Nelson D, Earle J, Jones C, Cascino T, Nichols D, Ivnik R, Hellman R, Curran W, Abrams R (2002) Prospective randomized trial of low- versus high-dose radiation therapy in adults with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/Eastern Cooperative Oncology Group study. J Clin Oncol 20:2267-2276 (Pubitemid 34441653)
4. Correa DD, De Angelis LM, Shi W, Thaler HT, Lin M, Abrey LE (2007) Cognitive functions in low-grade gliomas: disease and treatment effects. J Neurooncol 81:175-184 (Pubitemid 44963976)
5. Stupp R, Janzer RC, Hegi ME, Villemure JG, Mirimanoff RO (2003) Prognostic factors for low-grade gliomas. Semin Oncol 30:23-28 (Pubitemid 38199160)
6. Pace A, Vidiri A, Galie E, Carosi M, Telera S, Cianciulli AM, Canalini P, Giannarelli D, Jandolo B, Carapella CM (2003) Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and radiological response. Ann Oncol 14:1722-1726 (Pubitemid 38029042)
7. Quinn JA, Reardon DA, Friedman AH, Rich JN, Sampson JH, Provenzale JM, McLendon RE, Gururangan S, Bigner DD, Herndon JE II, Avgeropoulos N, Finlay J, Tourt-Uhlig S, Affronti ML, Evans B, Stafford-Fox V, Zaknoen S, Friedman HS (2003) Phase II trial of temozolomide in patients with progressive low-grade glioma. J Clin Oncol 21:646-651 (Pubitemid 46621898)
8. Brada M, Viviers L, Abson C, Hines F, Britton J, Ashley S, Sardell S, Traish D, Gonsalves A, Wilkins P, Westbury C (2003) Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas. Ann Oncol 14:1715-1721 (Pubitemid 38029041)
9. Hoang-Xuan K, Capelle L, Kujas M, Taillibert S, Duffau H, Lejeune J, Polivka M, Criniere E, Marie Y, Mokhtari K, Carpentier AF, Laigle F, Simon JM, Cornu P, Broet P, Sanson M, Delattre JY (2004) Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions. J Clin Oncol 22:3133-3138 (Pubitemid 41103727)
10. Kaloshi G, Benouaich-Amiel A, Diakite F, Taillibert S, Lejeune J, Laigle-Donadey F, Renard MA, Iraqi W, Idbaih A, Paris S, Capelle L, Duffau H, Cornu P, Simon JM, Mokhtari K, Polivka M, Omuro A, Carpentier A, Sanson M, Delattre JY, Hoang-Xuan K (2007) Temozolomide for low-grade gliomas: predictive impact of 1p/19q loss on response and outcome. Neurology 68:1831-1836 (Pubitemid 46791397)
11. Mariani L, Deiana G, Vassella E, Fathi AR, Murtin C, Arnold M, Vajtai I, Weis J, Siegenthaler P, Schobesberger M, Reinert MM (2006) Loss of heterozygosity 1p36 and 19q13 is a prognostic factor for overall survival in patients with diffuse WHO grade 2 gliomas treated without chemotherapy. J Clin Oncol 24:4758-4763 (Pubitemid 46630940)
12. Smith JS, Perry A, Borell TJ, Lee HK, O'Fallon J, Hosek SM, Kimmel D, Yates A, Burger PC, Scheithauer BW, Jenkins RB (2000) Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J Clin Oncol 18:636-645 (Pubitemid 30078545)
13. Newlands ES, Stevens MF, Wedge SR, Wheelhouse RT, Brock C (1997) Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat Rev 23:35-61 (Pubitemid 27273454)
14. Esteller M, Garcia-Foncillas J, Andion E, Goodman SN, Hidalgo OF, Vanaclocha V, Baylin SB, Herman JG (2000) Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 343:1350-1354
15. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997-1003 (Pubitemid 40349502)
16. Rivera AL, Pelloski CE, Gilbert MR, Colman H, De La Cruz C, Sulman EP, Bekele BN, Aldape KD (2010) MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma. Neuro Oncol 12:116-121
17. Colman H, Zhang L, Sulman EP, McDonald JM, Shooshtari NL, Rivera A, Popoff S, Nutt CL, Louis DN, Cairncross JG, Gilbert MR, Phillips HS, Mehta MP, Chakravarti A, Pelloski CE, Bhat K, Feuerstein BG, Jenkins RB, Aldape K (2010) A multigene predictor of outcome in glioblastoma. Neuro Oncol 12:49-57
18. Preusser M (2009) MGMT analysis at DNA, RNA and protein levels in glioblastoma tissue. Histol Histopathol 24:511-518
19. Levin N, Lavon I, Zelikovitsh B, Fuchs D, Bokstein F, Fellig Y, Siegal T (2006) Progressive low-grade oligodendrogliomas: response to temozolomide and correlation between genetic profile and O6-methylguanine DNA methyltransferase protein expression. Cancer 106:1759-1765
20. van den Bent MJ, Taphoorn MJ, Brandes AA, Menten J, Stupp R, Frenay M, Chinot O, Kros JM, van der Rijt CC, Vecht Ch J, Allgeier A, Gorlia T (2003) Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971. J Clin Oncol 21:2525-2528 (Pubitemid 46606334)
21. Pouratian N, Gasco J, Sherman JH, Shaffrey ME, Schiff D (2007) Toxicity and efficacy of protracted low dose temozolomide for the treatment of low grade gliomas. J Neurooncol 82:281-288 (Pubitemid 46614391)
22. Kesari S, Schiff D, Drappatz J, LaFrankie D, Doherty L, Macklin EA, Muzikansky A, Santagata S, Ligon KL, Norden AD, Ciampa A, Bradshaw J, Levy B, Radakovic G, Ramakrishna N, Black PM, Wen PY (2009) Phase II study of protracted daily temozolomide for low-grade gliomas in adults. Clin Cancer Res 15:330-337
23. Kreklau EL, Kurpad C, Williams DA, Erickson LC (1999) Prolonged inhibition of O(6)-methylguanine DNA methyltransferase in human tumor cells by O(6)-benzylguanine in vitro and in vivo. J Pharmacol Exp Ther 291:1269-1275
24. Hegi ME, Murat A, Lambiv WL, Stupp R (2006) Brain tumors: molecular biology and targeted therapies. Ann Oncol 17(suppl 10):x191-x197 (Pubitemid 44542008)
25. Dubbink HJ, Taal W, van Marion R, Kros JM, van Heuvel I, Bromberg JE, Zonnenberg BA, Zonnenberg CB, Postma TJ, Gijtenbeek JM, Boogerd W, Groenendijk FH, Smitt PA, Dinjens WN, van den Bent MJ (2009) IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide. Neurology 73:1792-1795
26. Watanabe T, Nakamura M, Kros JM, Burkhard C, Yonekawa Y, Kleihues P, Ohgaki H (2002) Phenotype versus genotype correlation in oligodendrogliomas and low-grade diffuse astrocytomas. Acta Neuropathol 103:267-275 (Pubitemid 36075328)
27. Everhard S, Kaloshi G, Criniere E, Benouaich-Amiel A, Lejeune J, Marie Y, Sanson M, Kujas M, Mokhtari K, Hoang-Xuan K, Delattre JY, Thillet J (2006) MGMT methylation: a marker of response to temozolomide in low-grade gliomas. Ann Neurol 60:740-743 (Pubitemid 46048490)
28. Mollemann M, Wolter M, Felsberg J, Collins VP, Reifenberger G (2005) Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors. Int J Cancer 113:379-385 (Pubitemid 40038704)
29. Sharma S, Salehi F, Scheithauer BW, Rotondo F, Syro LV, Kovacs K (2009) Role of MGMT in tumor development, progression, diagnosis, treatment and prognosis. Anticancer Res 29:3759-3768
30. Dunn J, Baborie A, Alam F, Joyce K, Moxham M, Sibson R, Crooks D, Husband D, Shenoy A, Brodbelt A, Wong H, Liloglou T, Haylock B, Walker C (2009) Extent of MGMT promoter methylation correlates with outcome in glioblastomas given temozolomide and radiotherapy. Br J Cancer 101:124-131